Cell therapy of pseudarthrosis.

Area of Science:

• Orthopedics
• Regenerative Medicine
• Biotechnology

Background:

• Pseudarthrosis, or nonunion of long bones, presents a significant clinical challenge.
• Current treatment options for nonunion may have limitations in efficacy and patient outcomes.

Purpose of the Study:

• To evaluate the safety and effectiveness of cell therapy for treating long bone nonunion.
• To compare autologous bone marrow aspirate implantation with mononuclear cells purified using Sepax® equipment.

Main Methods:

• A prospective comparative study involving six patients with tibial or femoral nonunion.
• Four patients received percutaneous autologous bone marrow aspirate infusion; two received autologous bone marrow mononuclear cells processed with Sepax®.
• Treatment involved closed procedures with no exposure of the nonunion site; outcomes assessed via physical examination and radiography at 2, 4, and 6 months.

Main Results:

• All patients achieved bone consolidation within 3 to 24 weeks, with no procedure-related complications.
• Patient satisfaction, measured by the adapted QALY scale, significantly increased from an average of two to nine post-treatment (p=0.0156).

Conclusions:

• Cell therapy, utilizing either bone marrow aspirate or Sepax®-purified cells, is a safe and effective treatment for long bone nonunion.
• The method demonstrates efficacy irrespective of the primary fixation technique employed.
• This study supports cell therapy as a viable option for managing challenging fracture nonunions.